- Home
- APRE vs GLYC Comparison
APRE vs GLYC Comparison
Compare APRE & GLYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- GLYC
- Stock Information
- Founded
- APRE 2006
- GLYC 2003
- Country
- APRE United States
- GLYC United States
- Employees
- APRE N/A
- GLYC N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- GLYC Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- GLYC Health Care
- Exchange
- APRE Nasdaq
- GLYC Nasdaq
- Market Cap
- APRE 15.8M
- GLYC 17.0M
- IPO Year
- APRE 2019
- GLYC 2014
- Fundamental
- Price
- APRE $4.08
- GLYC $0.26
- Analyst Decision
- APRE Strong Buy
- GLYC Hold
- Analyst Count
- APRE 2
- GLYC 2
- Target Price
- APRE $15.50
- GLYC N/A
- AVG Volume (30 Days)
- APRE 33.0K
- GLYC 507.0K
- Earning Date
- APRE 11-07-2024
- GLYC 11-13-2024
- Dividend Yield
- APRE N/A
- GLYC N/A
- EPS Growth
- APRE N/A
- GLYC N/A
- EPS
- APRE N/A
- GLYC N/A
- Revenue
- APRE $1,310,839.00
- GLYC $10,000.00
- Revenue This Year
- APRE $134.21
- GLYC N/A
- Revenue Next Year
- APRE N/A
- GLYC N/A
- P/E Ratio
- APRE N/A
- GLYC N/A
- Revenue Growth
- APRE 130.31
- GLYC N/A
- 52 Week Low
- APRE $2.15
- GLYC $0.14
- 52 Week High
- APRE $8.85
- GLYC $3.53
- Technical
- Relative Strength Index (RSI)
- APRE 62.50
- GLYC 49.67
- Support Level
- APRE $3.34
- GLYC $0.19
- Resistance Level
- APRE $4.41
- GLYC $0.28
- Average True Range (ATR)
- APRE 0.43
- GLYC 0.02
- MACD
- APRE 0.04
- GLYC 0.00
- Stochastic Oscillator
- APRE 54.19
- GLYC 39.17
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About GLYC GlycoMimetics Inc.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.